# Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study

Source: https://onco.cc/trials/nct07739485/  
OnCo record `nct07739485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of epirubicin in triple-negative breast cancer, run by Liu Shu, now recruiting.

## Summary

Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study is a phase 1/2, interventional study registered as NCT07739485 by Liu Shu, with a registry enrolment figure of 30 participants, started 2026-07-30 and due to reach its primary completion in 2027-07-30. Interventions recorded: Epirubicin and cyclophosphamide followed by paclitaxel oral solution. Conditions listed: Triple -Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Triple-negative breast cancer (TNBC) is defined as ER \<1%, PR \<1%, and HER2-negative \[IHC 0, IHC 1+, or IHC 2+ with FISH-negative\]". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: GBCF003
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07739485
- Phase: 1/2
- Setting: A Dose-Finding Study of Paclitaxel Oral Solution in Neoadjuvant Therapy for Patients With Triple Negative Breast Cancer
- Sponsor: Liu Shu
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07739485: https://clinicaltrials.gov/study/NCT07739485

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Epirubicin](https://onco.cc/drugs/epirubicin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07739485.json